Cantor Fitzgerald Analysts Cut Earnings Estimates for VERA

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Stock analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of Vera Therapeutics in a research report issued on Monday, May 12th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings per share of ($2.79) for the year, down from their previous estimate of ($2.74). Cantor Fitzgerald has a "Overweight" rating and a $100.00 price objective on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same quarter in the previous year, the company posted ($0.56) earnings per share.

Other research analysts also recently issued reports about the stock. The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They set a "buy" rating and a $58.00 target price for the company. Wolfe Research started coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 target price on the stock. HC Wainwright initiated coverage on Vera Therapeutics in a research note on Monday, May 5th. They set a "buy" rating and a $75.00 price target for the company. Guggenheim boosted their price objective on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Vera Therapeutics currently has an average rating of "Buy" and a consensus target price of $63.33.

Vera Therapeutics Stock Performance

VERA traded down $0.08 during trading on Wednesday, hitting $21.25. 955,320 shares of the company traded hands, compared to its average volume of 780,251. Vera Therapeutics has a one year low of $18.53 and a one year high of $51.61. The stock's fifty day moving average is $23.49 and its 200 day moving average is $34.01. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1.35 billion, a P/E ratio of -8.14 and a beta of 1.28.

Institutional Trading of Vera Therapeutics

Several institutional investors have recently bought and sold shares of the company. Vestal Point Capital LP boosted its stake in shares of Vera Therapeutics by 132.6% in the 1st quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company's stock worth $60,050,000 after buying an additional 1,425,000 shares during the last quarter. Avoro Capital Advisors LLC grew its holdings in Vera Therapeutics by 30.2% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock valued at $237,247,000 after buying an additional 1,300,410 shares in the last quarter. Lord Abbett & CO. LLC lifted its stake in Vera Therapeutics by 170.8% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,153,670 shares of the company's stock worth $48,788,000 after purchasing an additional 727,656 shares in the last quarter. Federated Hermes Inc. boosted its stake in Vera Therapeutics by 162.2% during the fourth quarter. Federated Hermes Inc. now owns 1,085,986 shares of the company's stock valued at $45,926,000 after buying an additional 671,881 shares during the last quarter. Finally, Integral Health Asset Management LLC increased its stake in Vera Therapeutics by 130.0% in the 4th quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company's stock worth $48,634,000 after acquiring an additional 650,000 shares during the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.